IBDEI151 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20384,1,5,0)
 ;;=5^Cellulitis Of Toe
 ;;^UTILITY(U,$J,358.3,20384,2)
 ;;=^271885
 ;;^UTILITY(U,$J,358.3,20385,0)
 ;;=682.2^^131^1287^12
 ;;^UTILITY(U,$J,358.3,20385,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20385,1,4,0)
 ;;=4^682.2
 ;;^UTILITY(U,$J,358.3,20385,1,5,0)
 ;;=5^Cellulitis Of Trunk
 ;;^UTILITY(U,$J,358.3,20385,2)
 ;;=^271890
 ;;^UTILITY(U,$J,358.3,20386,0)
 ;;=070.1^^131^1287^26
 ;;^UTILITY(U,$J,358.3,20386,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20386,1,4,0)
 ;;=4^070.1
 ;;^UTILITY(U,$J,358.3,20386,1,5,0)
 ;;=5^Hepatitis A 
 ;;^UTILITY(U,$J,358.3,20386,2)
 ;;=^126486
 ;;^UTILITY(U,$J,358.3,20387,0)
 ;;=070.30^^131^1287^27
 ;;^UTILITY(U,$J,358.3,20387,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20387,1,4,0)
 ;;=4^070.30
 ;;^UTILITY(U,$J,358.3,20387,1,5,0)
 ;;=5^Hepatitis B, Acute
 ;;^UTILITY(U,$J,358.3,20387,2)
 ;;=^266626
 ;;^UTILITY(U,$J,358.3,20388,0)
 ;;=070.32^^131^1287^28
 ;;^UTILITY(U,$J,358.3,20388,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20388,1,4,0)
 ;;=4^070.32
 ;;^UTILITY(U,$J,358.3,20388,1,5,0)
 ;;=5^Hepatitis B, Chronic
 ;;^UTILITY(U,$J,358.3,20388,2)
 ;;=^303249
 ;;^UTILITY(U,$J,358.3,20389,0)
 ;;=070.51^^131^1287^29
 ;;^UTILITY(U,$J,358.3,20389,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20389,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,20389,1,5,0)
 ;;=5^Hepatitis C, Acute
 ;;^UTILITY(U,$J,358.3,20389,2)
 ;;=^266632
 ;;^UTILITY(U,$J,358.3,20390,0)
 ;;=070.54^^131^1287^30
 ;;^UTILITY(U,$J,358.3,20390,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20390,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,20390,1,5,0)
 ;;=5^Hepatitis C, Chronic
 ;;^UTILITY(U,$J,358.3,20390,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,20391,0)
 ;;=571.41^^131^1287^32
 ;;^UTILITY(U,$J,358.3,20391,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20391,1,4,0)
 ;;=4^571.41
 ;;^UTILITY(U,$J,358.3,20391,1,5,0)
 ;;=5^Hepatitis, Chronic Persist
 ;;^UTILITY(U,$J,358.3,20391,2)
 ;;=^259093
 ;;^UTILITY(U,$J,358.3,20392,0)
 ;;=571.1^^131^1287^33
 ;;^UTILITY(U,$J,358.3,20392,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20392,1,4,0)
 ;;=4^571.1
 ;;^UTILITY(U,$J,358.3,20392,1,5,0)
 ;;=5^Hepatitis, ETOH acute
 ;;^UTILITY(U,$J,358.3,20392,2)
 ;;=^2597
 ;;^UTILITY(U,$J,358.3,20393,0)
 ;;=070.59^^131^1287^34
 ;;^UTILITY(U,$J,358.3,20393,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20393,1,4,0)
 ;;=4^070.59
 ;;^UTILITY(U,$J,358.3,20393,1,5,0)
 ;;=5^Hepatitis, Other Viral
 ;;^UTILITY(U,$J,358.3,20393,2)
 ;;=Hepatitis, Other Viral^266631
 ;;^UTILITY(U,$J,358.3,20394,0)
 ;;=V08.^^131^1287^24
 ;;^UTILITY(U,$J,358.3,20394,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20394,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,20394,1,5,0)
 ;;=5^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,20394,2)
 ;;=HIV + Status (Asymptomatic)^303392
 ;;^UTILITY(U,$J,358.3,20395,0)
 ;;=042.^^131^1287^25
 ;;^UTILITY(U,$J,358.3,20395,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20395,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,20395,1,5,0)
 ;;=5^HIV Disease (symptomatic)
 ;;^UTILITY(U,$J,358.3,20395,2)
 ;;=HIV Disease (symptomatic)^266500
 ;;^UTILITY(U,$J,358.3,20396,0)
 ;;=464.00^^131^1287^2
 ;;^UTILITY(U,$J,358.3,20396,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20396,1,4,0)
 ;;=4^464.00
 ;;^UTILITY(U,$J,358.3,20396,1,5,0)
 ;;=5^Acute Laryngitis
 ;;^UTILITY(U,$J,358.3,20396,2)
 ;;=Acute Laryngitis^323469
 ;;^UTILITY(U,$J,358.3,20397,0)
 ;;=790.6^^131^1287^1
 ;;^UTILITY(U,$J,358.3,20397,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20397,1,4,0)
 ;;=4^790.6
 ;;^UTILITY(U,$J,358.3,20397,1,5,0)
 ;;=5^Abnormal LFT's
 ;;^UTILITY(U,$J,358.3,20397,2)
 ;;=^87228
